Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHansoh BioMedical R&D Company
About this trial
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Eligibility criteria
Qualifiers
Males or females aged 18 - 75 years (inclusive).
Histologically confirmed unresectable, recurrent or metastatic solid tumors.
At least one target lesion per the RECIST v1.1.
ECOG performance status of 0-1.
Disqualifiers
Any anticancer therapy targeting MET, including TKIs, antibodies or antibody-drug conjugates.
Monoclonalor bispecific antibodies targeting EGFR.
Systemic anti-cancer treatment (Cytotoxicities and anti-cancer Traditional Chinese medicine or TKIs) within 2 weeks prior to the first dose of HS-20117.
Investigational anti-cancer drugs or antibodies or ADCs within 4 weeks prior to the first dose of HS-20117.
Trial design
Treatments tested in this trial
- HS-20117 combined HS-20093
- HS-20117 combined Platinum-containing chemotherapy
- HS-20117 combined HS-20093 and 5-FU
- HS-20117+CAPEOX
- HS-20117+FOLFIRI
- HS-20117+mFOLFOX6
Treatment groups
780 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov